BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Takeda divests select non-core assets for $562 M

09 September 2020 | News

Portfolio includes prescription products in Takeda's Cardiovascular/Metabolic and Anti-inflammatory therapeutic areas along with Calcium

Japanese firm Takeda Pharmaceutical has announced that it has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm.

Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of successfully acquiring, integrating and growing pharmaceutical products.

Takeda will receive an upfront payment of approximately $562 million, subject to customary legal and regulatory closing conditions.

The portfolio to be divested to Cheplapharm is comprised of non-core prescription pharmaceutical products in a variety of therapeutic categories sold predominantly in Europe and Canada. This includes Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium.

The portfolio generated FY 2019 net sales of approximately $260 million. While the products included in the sale address key patient needs in these countries, they are outside of Takeda's five key business areas.

With a more focused portfolio, the divestiture further enables Takeda's Europe & Canada Business Unit (EUCAN) to focus on and drive strategic core growth areas. In April 2020, Takeda announced to divest EUCAN's non-core over-the-counter (OTC) products to Orifarm Group.